Compare AbCellera Biologics Inc (ABCL) vs FedEx Corporation (FDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs FedEx Corporation — how do they compare? AbCellera Biologics Inc trades at $7.29 (market cap $2.35B), while FedEx Corporation trades at $308.82 (market cap $74.66B). The key difference: FedEx Corporation is far larger — about 31.8× AbCellera Biologics Inc's market cap, and FedEx Corporation pays a 1.56% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | FDX | |
|---|---|---|
Market Cap | $2.35B | $74.66B |
Sector | Health | Industrials |
52-Week High | $8.12 | $338.75 |
52-Week Low | $2.78 | $174.81 |
Enterprise Value | $1.99B | $108.67B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
FedEx trades at $312.88, down slightly by 0.04% on the day, with a bearish technical signal from moving averages. Recent quarterly earnings have consistently beaten expectations, including Q1 2026 EPS of $6.31 versus $5.91 expected. The company is streamlining operations, highlighted by the sale of its supply chain unit to CMA CGM for $1.4 billion, while maintaining solid cash flow from operations of $7.04 billion in 2025.
The outlook is mixed: analyst consensus is bullish with a $365.73 price target, but margin recovery remains uncertain. Key risks include soft shipping demand and ongoing cost pressures. Upside potential hinges on successful execution of efficiency initiatives like DRIVE and Network 2.0 to expand profitability beyond current 4.88% net margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
